← FDA DRUG APPROVALS

FDA ANDA · ANDA064210

STREPTOMYCIN

Sponsor: XGEN PHARMS

APPLICATION
ANDA064210
TYPE
ANDA
ORIGINAL APPROVAL
1998-06-30
LATEST ACTION
2023-02-10
ROUTE
INTRAMUSCULAR, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

STREPTOMYCIN SULFATEPrescription
STREPTOMYCIN SULFATE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2023-02-10Labeling · Supplement 16 · standardAP
2015-11-10Labeling · Supplement 12 · standardAP
2012-04-30Labeling · Supplement 9LabelAP
2001-07-23Manufacturing (CMC) · Supplement 2AP
2001-07-23Manufacturing (CMC) · Supplement 3AP
2000-05-11Manufacturing (CMC) · Supplement 1AP
1998-06-30OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →